Navigation Links
Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
Date:11/12/2008

Left untreated, urea cycle disorders can cause dangerously heightened levels of ammonia in the bloodstream (hyperammonemia) resulting in brain damage, coma, and/or death.

About HPN-100

HPN-100 is a pro-drug of phenylbutyrate and a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL(R), the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle deficiencies including those related to carbamylphosphate synthetase, ornithine transcarbamylase and argininosuccinic acid synthetase. HPN-100, which is dosed orally in liquid form, provides an alternative pathway to the urea cycle for the disposal of waste nitrogen through the renal excretion of phenylacetylglutamine, which is formed from phenylacetic acid and glutamine.

About BUPHENYL(R)

BUPHENYL(R) is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). BUPHENYL(R) should not be administered to patients with known hypersensitivity to sodium phenylbutyrate or any component of this preparation. The most common adverse reactions associated with BUPHENYL(R) were amenorrhea dysfunction, decreased appetite, body odor (probably caused by its metabolite phenylacetate) and bad taste or taste aversion. Patients with urea cycle disorders should not take valproic acid, haloperidol, or steroids as these drugs have been reported to increase blood ammonia levels, and probenecid may affect the kidneys' excretion. Use with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states where there is sodium retention with edema. Use caution when administering to patients with hepatic or renal insufficiency or inborn errors of beta oxidation. The safety or efficacy of doses in excess of 20 gra
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Hyperion Therapeutics Elects Lota Zoth to Board of Directors
2. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
3. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
4. Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product
5. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
6. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
7. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
8. Cornerstone Therapeutics Announces New Board of Directors
9. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
10. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
11. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Texas (PRWEB) July 25, 2014 Yisrayl Hawkins, ... Texas, is once again stirring the pot by revealing to ... they are deceived into worshipping Satan, the devil, in his ... clever plan organized by Satan, and carried out by the ... of the Creator from the Inspired Holy Scriptures and replacing ...
(Date:7/25/2014)... 2014 According to the Liver ... by Vkool.com, this is a comprehensive guide that ... and safe remedies for liver cirrhosis . ...     Chapter 1: Liver Cirrhosis Bible ... Learn About Liver Basics ,     Chapter 3: ...
(Date:7/24/2014)... July 25, 2014 iFitDress.com, a renowned ... new range of casual party dresses . According ... party gowns are now offered at discounted prices, up ... this morning until August 04. , Most of ... in the global market. They are popular for special ...
(Date:7/24/2014)... nighttime production of the hormone melatonin, renders breast cancer ... drug, says a new study by Tulane University School ... Disruption by Exposure to Light at Night Drives Intrinsic ... the journal Cancer Research , is the first ... of tamoxifen in treating breast cancer. , , Principal ...
(Date:7/24/2014)... The report, “Content Delivery Networks (CDN) Market”, ... sub-segments with an in-depth analysis and forecasting of ... for this market with insights on trends, opportunities, ... and 36 figures spread through 157 pages and ... at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early buyers ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4
... Therapy for Cardiovascular Disease (IC3D) is a three-day ... cell-based therapies for treating cardiovascular diseases. The theme ... Building Blocks: Strategies for Cardiovascular Reconstruction in 2009." ... present basic, core discussions on stem cell science ...
... our troops" is no longer just,a slogan -- it,s ... and a,new marketing campaign for the renamed Bob ... JWT Atlanta., By focusing on the physical and ... and raising money to provide,resources and support for injured ...
... for Invisicare Is Put In Place, LAS ... SKVI), the developers of Invisicare, a patented polymer,delivery ... appointment of Geert Cauwenbergh, PhD to head its ... to expand the demand,for Invisicare in international markets. ...
... HOUSTON, Nov. 6 US Oncology, Inc. ("US Oncology" ... services companies,reported revenue of $821.7 million, EBITDA of $54.5 ... million and operating cash flow,of $35.1 million for the ... ended September 30, 2008, US Oncology reported revenue of ...
... MOUNT LAUREL, N.J., Nov. 6 At ... Inc. (Nasdaq: MEDQ ) is introducing ... top-ranked,interactive front-end speech recognition application, and RadWorkFlow(R), ... RadWorkFlow offers an efficient, simplified, and ...
... LIMS System Chosen by Hospital to Replace ... Global Med Technologies(R),Inc. ("Global Med" or ... e-Health, medical information technology company, today,announced that ... Laboratory,Information Management Software (marketed as "Labo Serveur" ...
Cached Medicine News:Health News:5th Annual Global Conference on Stem Cell Therapy to be held Jan. 13-16, 2009 in NYC 2Health News:Bob Woodruff Foundation and JWT Introduce Marketing Campaign and Unveil www.ReMIND.org 2Health News:Bob Woodruff Foundation and JWT Introduce Marketing Campaign and Unveil www.ReMIND.org 3Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 2Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 3Health News:US Oncology Reports Third Quarter 2008 Results 2Health News:US Oncology Reports Third Quarter 2008 Results 3Health News:US Oncology Reports Third Quarter 2008 Results 4Health News:US Oncology Reports Third Quarter 2008 Results 5Health News:US Oncology Reports Third Quarter 2008 Results 6Health News:US Oncology Reports Third Quarter 2008 Results 7Health News:US Oncology Reports Third Quarter 2008 Results 8Health News:US Oncology Reports Third Quarter 2008 Results 9Health News:US Oncology Reports Third Quarter 2008 Results 10Health News:US Oncology Reports Third Quarter 2008 Results 11Health News:US Oncology Reports Third Quarter 2008 Results 12Health News:US Oncology Reports Third Quarter 2008 Results 13Health News:US Oncology Reports Third Quarter 2008 Results 14Health News:US Oncology Reports Third Quarter 2008 Results 15Health News:US Oncology Reports Third Quarter 2008 Results 16Health News:US Oncology Reports Third Quarter 2008 Results 17Health News:US Oncology Reports Third Quarter 2008 Results 18Health News:US Oncology Reports Third Quarter 2008 Results 19Health News:US Oncology Reports Third Quarter 2008 Results 20Health News:US Oncology Reports Third Quarter 2008 Results 21Health News:US Oncology Reports Third Quarter 2008 Results 22Health News:US Oncology Reports Third Quarter 2008 Results 23Health News:MedQuist Introduces SpeechQ for Radiology Integrated with RadWorkFlow 2Health News:MedQuist Introduces SpeechQ for Radiology Integrated with RadWorkFlow 3Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 2Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 3Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 4
(Date:7/24/2014)... , July 24, 2014  In any given hospital ... 25 patients has at least one hospital-acquired infection, according ... more, many of these infections prove fatal. And as ... alarming number of patient deaths per year, infection control ... Consequently, a stronger emphasis is being ...
(Date:7/24/2014)... DALLAS , July 24, 2014 /PRNewswire-iReach/ -- ... days once order is placed. Photo ... is a professional and in-depth market survey on ... firstly reviews the basic information of Hemodialysis Machine ... report then explores global and China,s top manufacturers ...
(Date:7/24/2014)... -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) today ... 2014. Three Months Ended 06/30/14Three Months Ended 06/30/13 ,  Percentage ... 51% Non-GAAP Net Sales , $278.8 Million , $196.1 ... , $1.12 , 37% Non-GAAP Diluted ... 37%  Six Months Ended 06/30/14Six Months Ended 06/30/13 , ...
Breaking Medicine Technology:Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28
... WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS ... today announced that it has appointed world-renowned clinical genomics ... Scientific Advisory Board.   Dr. Chinnaiyan is ... the clinic to choose appropriate therapies for cancer patients. ...
... SAN DIEGO, Jan. 19, 2011 ADVENTRX Pharmaceuticals, Inc. (NYSE ... Food and Drug Administration (FDA) has established a Prescription Drug ... the review of the Exelbine (ANX-530) New Drug Application (NDA). ... that the application is sufficiently complete to permit a substantive ...
Cached Medicine Technology:WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 2WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 3WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 4ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA 2ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA 3
... are individually adjusted for perfect focus where ... on paper. This, along with Keeler's wide ... that whatever the patient's pupil size, you ... of view. Lithium-ion technology provides a longer ...
... 200 ophthalmoscope, the world's ... ophthalmoscope. Heine's aspherical optical ... along with innovative design ... the Beta 200 the ...
... The Heine Beta 200S is ... with a combination of patented ... and a range of corrective ... dpt. in single diopter steps. ...
... The ophthalmoscope with superior aspherical optics. The ... means of the aspherical optical system avoids ... 200 allows you to view the whole ... even with a small pupil. Conventional ophthalmoscopes ...
Medicine Products: